Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) announced that CEO Michael Halstead will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York City. The event, scheduled for Sept. 16 at 8:30 a.m. EDT, will be webcast live, with a replay available on the Events & Presentations page of Helus Pharma's investor relations website. This participation matters because it offers the company a prominent stage to engage with potential investors, analysts, and healthcare industry leaders, potentially boosting visibility and credibility for its pipeline of novel mental health treatments.
Helus Pharma, the commercial operating name of Cybin Inc., is a clinical-stage pharmaceutical company focused on developing proprietary novel serotonergic agonists (NSAs)—synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The company aims to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions. With class-leading data, Helus Pharma seeks to improve the treatment landscape through NSAs that provide durable improvements in mental health.
The company is currently developing HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004, another proprietary NSA, is in Phase 2 for generalized anxiety disorder. Helus Pharma also maintains an extensive research portfolio of investigational NSAs. Operating in Canada, the United States, the United Kingdom, and Ireland, the company is positioning itself as a key player in the neuropsychiatric space.
Investors and industry watchers should note that this conference appearance could serve as a catalyst for increased attention to Helus Pharma's clinical milestones. The fireside chat may provide updates on the company's progress, strategic direction, and the potential of its NSA platform. For those unable to attend in person, the live webcast and subsequent replay ensure broad access to the discussion. To view the full press release, visit https://ibn.fm/r0jfC. For more information about Helus Pharma, visit www.helus.com or follow the team on X, LinkedIn, YouTube, and Instagram. The latest news and updates relating to HELP are available in the company's newsroom at https://ibn.fm/HELP.
BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences, disseminated this announcement. As part of its services, BioMedWire provides access to a vast network of wire solutions, article and editorial syndication to over 5,000 outlets, enhanced press release optimization, social media distribution, and tailored corporate communications solutions. This broad reach ensures that news like Helus Pharma's conference participation reaches a wide audience of investors, influencers, consumers, journalists, and the general public.
